Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.67%345.221.2%$624.02m
GILDGilead Sciences, Inc.
-3.53%72.920.9%$510.71m
CELGCelgene Corporation
0.24%90.371.2%$496.41m
AMGNAmgen Inc.
0.50%197.421.2%$485.34m
ILMNIllumina, Inc.
-0.34%325.883.5%$373.70m
REGNRegeneron Pharmaceuticals, Inc.
0.67%374.262.6%$315.78m
VRTXVertex Pharmaceuticals Incorporated
0.64%176.081.9%$209.08m
ALXNAlexion Pharmaceuticals, Inc.
-1.09%116.002.0%$186.59m
AAgilent Technologies, Inc.
-1.28%64.661.5%$159.27m
SRPTSarepta Therapeutics, Inc.
0.52%130.2516.6%$142.46m
NKTRNektar Therapeutics
0.13%60.035.6%$126.29m
BLUEBluebird Bio, Inc.
1.15%158.0014.6%$121.57m
EXASExact Sciences Corporation
0.33%48.8425.3%$118.82m
BMRNBioMarin Pharmaceutical Inc.
0.69%101.014.4%$118.74m
INCYIncyte Corporation
1.40%68.802.5%$111.73m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.